X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STRIDES SHASUN LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STRIDES SHASUN LTD TORRENT PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 29.0 15.2 190.5% View Chart
P/BV x 5.5 1.8 312.5% View Chart
Dividend Yield % 1.0 0.6 176.0%  

Financials

 TORRENT PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
STRIDES SHASUN LTD
Mar-17
TORRENT PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,275 138.7%   
Low Rs1,186918 129.2%   
Sales per share (Unadj.) Rs346.1389.6 88.8%  
Earnings per share (Unadj.) Rs55.228.0 197.3%  
Cash flow per share (Unadj.) Rs73.348.9 149.9%  
Dividends per share (Unadj.) Rs14.004.50 311.1%  
Dividend yield (eoy) %0.90.4 231.0%  
Book value per share (Unadj.) Rs257.1303.1 84.8%  
Shares outstanding (eoy) m169.2289.42 189.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.32.8 151.6%   
Avg P/E ratio x26.839.2 68.3%  
P/CF ratio (eoy) x20.122.4 89.8%  
Price / Book Value ratio x5.73.6 158.8%  
Dividend payout %25.416.1 157.7%   
Avg Mkt Cap Rs m249,88798,036 254.9%   
No. of employees `00011.85.8 203.1%   
Total wages/salary Rs m9,9345,881 168.9%   
Avg. sales/employee Rs Th4,971.56,005.9 82.8%   
Avg. wages/employee Rs Th843.21,014.0 83.2%   
Avg. net profit/employee Rs Th792.4431.2 183.8%   
INCOME DATA
Net Sales Rs m58,56934,834 168.1%  
Other income Rs m2,2331,686 132.5%   
Total revenues Rs m60,80236,520 166.5%   
Gross profit Rs m13,7736,428 214.3%  
Depreciation Rs m3,0691,872 164.0%   
Interest Rs m2,0562,269 90.6%   
Profit before tax Rs m10,8813,973 273.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,545470 328.7%   
Profit after tax Rs m9,3362,501 373.3%  
Gross profit margin %23.518.5 127.4%  
Effective tax rate %14.211.8 120.0%   
Net profit margin %15.97.2 222.0%  
BALANCE SHEET DATA
Current assets Rs m53,84138,165 141.1%   
Current liabilities Rs m31,61230,402 104.0%   
Net working cap to sales %38.022.3 170.3%  
Current ratio x1.71.3 135.7%  
Inventory Days Days9777 125.7%  
Debtors Days Days84104 80.2%  
Net fixed assets Rs m42,07937,639 111.8%   
Share capital Rs m846894 94.6%   
"Free" reserves Rs m42,65526,210 162.7%   
Net worth Rs m43,50127,105 160.5%   
Long term debt Rs m22,40816,377 136.8%   
Total assets Rs m101,25081,168 124.7%  
Interest coverage x6.32.8 228.8%   
Debt to equity ratio x0.50.6 85.3%  
Sales to assets ratio x0.60.4 134.8%   
Return on assets %11.35.9 191.4%  
Return on equity %21.59.2 232.6%  
Return on capital %19.612.1 162.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m20,06613,465 149.0%   
Fx outflow Rs m5,3044,076 130.1%   
Net fx Rs m14,7629,389 157.2%   
CASH FLOW
From Operations Rs m10,1272,881 351.5%  
From Investments Rs m-7,869-7,051 111.6%  
From Financial Activity Rs m-1,9183,382 -56.7%  
Net Cashflow Rs m212-788 -26.9%  

Share Holding

Indian Promoters % 71.5 27.7 258.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 37.8 18.6%  
FIIs % 12.6 8.6 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 25.9 34.0%  
Shareholders   26,511 56,241 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - NATCO PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS